ReviewActa pharmacologica Sinica2026
Sweetening the bonds: how O-GlcNAcylation modulates cell adhesion.
Review in Acta pharmacologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
O-GlcNAcylation is a dynamic, reversible post-translational modification that attaches N-acetylglucosamine (GlcNAc) to the serine or threonine residues of intracellular proteins. Catalysed by O-GlcNAc transferase and removed by O-GlcNAcase, this modification acts as a key nutrient and stress sensor. Although cell adhesion is fundamental to tissue architecture and mechanotransduction, emerging evidence has shown that O-GlcNAcylation profoundly orchestrates these processes. By modulating the composition and signalling of adhesion complexes, O-GlcNAcylation regulates both cell-cell and cell-matrix interactions. Through crosstalk with phosphorylation, this modification drives cellular adhesion plasticity, with broad implications for development, immunity, and diseases, such as cancer and neurodegeneration. Recent advances revealed that O-GlcNAcylation fine-tunes key regulators, including Focal Adhesion Kinase (FAK), Zyxin, and integrins, to control focal adhesion turnover. These mechanistic insights pave the way for novel therapeutic strategies targeting glycosylation-dependent adhesion signalling.
Indexed as
Identifiers
42332029What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.